Table I.
Patient characteristics.
| LEM, n | Placebo, n | |
|---|---|---|
| Entry | 23 | 24 |
| Age, years | ||
| Mean (range) | 62.0 (31–85) | 57.5 (42–77) |
| Tumor stage | ||
| 0 | 0 | 0 |
| 1 | 6 | 9 |
| 2 | 14 | 12 |
| 3 | 3 | 3 |
| 4 | 0 | 0 |
| T stage | ||
| Tis | 0 | 0 |
| T0 | 2 | 0 |
| T1 | 10 | 10 |
| T2 | 10 | 12 |
| T3 | 1 | 0 |
| T4 | 0 | 0 |
| Unknown | 0 | 2 |
| N stage | ||
| N0 | 11 | 16 |
| N1 | 10 | 5 |
| N2 | 2 | 2 |
| N3 | 0 | 1 |
| Treatments | ||
| FEC/FAC therapy | 10 | 12 |
| AC/EC therapy | 13 | 12 |
LEM, Lentinula edodes mycelia extract; FEC, 5-FU + cyclophosphamide + epirubicin; FAC, 5-FU + cyclophosphamide + doxorubicin/pirarubicin; AC, cyclophosphamide + doxorubicin/pirarubicin; EC, cyclophosphamide + epirubicin; 5-FU, 5- fluorouracil.